Drugs / 4-bromo-2,5-dimethoxyphenethylamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05523401 | Aug 2023 → Oct 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-bromo-2,5-dimethoxyphenethylamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05523401 ↗ |
| Action | Activate | “The 2C drugs act mainly as agonists on the 5-HT2A receptor” NCT05523401 ↗ |
| Modality | Small molecule | “2C-B is a phenethylamine” NCT05523401 ↗ |